Frontiers in Oncology (Jan 2022)

Non-Coding RNAs Regulate the Resistance to Anti-EGFR Therapy in Colorectal Cancer

  • Jinjin Chu,
  • Xianzhu Fang,
  • Zhonghou Sun,
  • Linlin Gai,
  • Wenqing Dai,
  • Haibo Li,
  • Xinyi Yan,
  • Jinke Du,
  • Lili Zhang,
  • Lu Zhao,
  • Donghua Xu,
  • Shushan Yan

DOI
https://doi.org/10.3389/fonc.2021.801319
Journal volume & issue
Vol. 11

Abstract

Read online

Colorectal cancer (CRC) is the third prevalent cancer worldwide, the morbidity and mortality of which have been increasing in recent years. As molecular targeting agents, anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (McAbs) have significantly increased the progression-free survival (PFS) and overall survival (OS) of metastatic CRC (mCRC) patients. Nevertheless, most patients are eventually resistant to anti-EGFR McAbs. With the intensive study of the mechanism of anti-EGFR drug resistance, a variety of biomarkers and pathways have been found to participate in CRC resistance to anti-EGFR therapy. More and more studies have implicated non-coding RNAs (ncRNAs) primarily including microRNAs (miRNAs), long non-coding RNAs (lncRNAs), and circular RNAs (circRNAs), are widely involved in tumorigenesis and tumor progression. They function as essential regulators controlling the expression and function of oncogenes. Increasing data have shown ncRNAs affect the resistance of molecular targeted drugs in CRC including anti-EGFR McAbs. In this paper, we have reviewed the advance in mechanisms of ncRNAs in regulating anti-EGFR McAbs therapy resistance in CRC. It provides insight into exploring ncRNAs as new molecular targets and prognostic markers for CRC.

Keywords